Last reviewed · How we verify
Extraneal (ICODEXTRIN)
At a glance
| Generic name | ICODEXTRIN |
|---|---|
| Sponsor | Vantive Us Hlthcare |
| Drug class | icodextrin |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
| First approval | 2002 |
Approved indications
Common side effects
- Peritonitis
- Upper respiratory infection
- Hypertension
- Rash
- Headache
- Abdominal Pain
- Flu syndrome
- Nausea
- Cough increase
- Edema
- Accidental injury
- Chest pain
Serious adverse events
- Exfoliative dermatitis
- Hyponatremia (serum sodium < 125 mmol/L)
Key clinical trials
- Efficacy and Safety of XyloCore Peritoneal Dialysis Solution. (PHASE3)
- Effectiveness of Two Icodextrin Exchanges on Fluid Status and Blood Pressure Control Compared to a Single Icodextrin Exchange (NA)
- Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients (PHASE3)
- IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients (PHASE4)
- IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients (PHASE3)
- Heart Failure and Peritoneal Ultrafiltration (PHASE2)
- Assessment of Bioimpedance and Vitamin D and LV Mass in PD Patients (FLUID Study) (PHASE2)
- PMCF Study for ADEPT® in LaparoscopicGynecologic Surgery
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |